AIM ImmunoTech to Participate in Solve M.E. and The Biotechnology Innovation Organization (BIO) Virtual Event, “Long Covid: What Will It Take To Accelerate Therapeutic Progress?”
17 févr. 2023 08h55 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., Feb. 17, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
AIM ImmunoTech Enters into Pancreatic Cancer Clinical Research Agreements with AstraZeneca and Erasmus Medical Center
17 janv. 2023 08h45 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., Jan. 17, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
AIMイムノテック (AIM ImmunoTech)、アストラゼネカ (AstraZeneca) およびエラスムスメディカルセンター (Erasmus Medical Center) と、膵臓がんに関する臨床研究契約を締結
17 janv. 2023 08h45 HE
|
AIM ImmunoTech Inc.
フロリダ州オカラ発, Jan. 17, 2023 (GLOBE NEWSWIRE) -- 複数のタイプのがんや免疫障害、ウイルス性疾患 (SARS-CoV-2ウイルスが原因で発症する新型コロナウイルス感染症を含む) の治療法の研究開発に注力する免疫製薬会社であるAIMイムノテック (AIM ImmunoTech Inc: AIM)...
AIM ImmunoTech与AstraZeneca和伊拉斯谟医疗中心签订胰腺癌临床研究协议
17 janv. 2023 08h45 HE
|
AIM ImmunoTech Inc.
佛罗里达州奥卡拉, Jan. 17, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc.（纽约证券交易所代码：AIM）（以下简称“AIM...
AIM ImmunoTech Broadens Patent Portfolio with New Netherlands Utility Patent Covering Ampligen® and Other AIM-Developed dsRNA Products to Include Rugged dsRNA for Use in COVID-19 Treatment or Prevention
09 janv. 2023 08h05 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., Jan. 09, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
AIM ImmunoTech to Present at the ‘Virtual Investor 2023 Companies to Watch Event’
05 janv. 2023 08h45 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., Jan. 05, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
AIM ImmunoTech Appoints Christopher McAleer, Ph.D. as Scientific Officer
12 déc. 2022 09h00 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., Dec. 12, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
AIM ImmunoTech Reports Positive Safety, Tolerability and Biological Activity Data for Intranasal Ampligen® (Rintatolimod) in Healthy Subjects
08 déc. 2022 08h05 HE
|
AIM ImmunoTech Inc.
Intranasal administration of Ampligen demonstrated to be well-tolerated Based on data generated to date, Ampligen could have potential as a prophylactic or early treatment against respiratory viral...
AIM ImmunoTech Announces Abstract Accepted for Poster Presentation at the British Society for Immunology Congress 2022
02 déc. 2022 10h45 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., Dec. 02, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
AIM ImmunoTech Reports Third Quarter 2022 Financial Results and Provides Corporate Update
15 nov. 2022 07h00 HE
|
AIM ImmunoTech Inc.
– Company continues to execute and is well-positioned to achieve multiple near-term clinical and regulatory value-driving milestones – Cash position expected to fund operations through end of 2023 ...